JP2013502933A5 - - Google Patents

Download PDF

Info

Publication number
JP2013502933A5
JP2013502933A5 JP2012527054A JP2012527054A JP2013502933A5 JP 2013502933 A5 JP2013502933 A5 JP 2013502933A5 JP 2012527054 A JP2012527054 A JP 2012527054A JP 2012527054 A JP2012527054 A JP 2012527054A JP 2013502933 A5 JP2013502933 A5 JP 2013502933A5
Authority
JP
Japan
Prior art keywords
asm
dose
hours
acid sphingomyelinase
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527054A
Other languages
English (en)
Japanese (ja)
Other versions
JP5955219B2 (ja
JP2013502933A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/047057 external-priority patent/WO2011025996A2/en
Publication of JP2013502933A publication Critical patent/JP2013502933A/ja
Publication of JP2013502933A5 publication Critical patent/JP2013502933A5/ja
Application granted granted Critical
Publication of JP5955219B2 publication Critical patent/JP5955219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527054A 2009-08-28 2010-08-28 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法 Active JP5955219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
US61/238,113 2009-08-28
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016041242A Division JP6251307B2 (ja) 2009-08-28 2016-03-03 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法

Publications (3)

Publication Number Publication Date
JP2013502933A JP2013502933A (ja) 2013-01-31
JP2013502933A5 true JP2013502933A5 (enExample) 2013-10-17
JP5955219B2 JP5955219B2 (ja) 2016-07-20

Family

ID=43625265

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2012527054A Active JP5955219B2 (ja) 2009-08-28 2010-08-28 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2016041242A Active JP6251307B2 (ja) 2009-08-28 2016-03-03 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2017226255A Pending JP2018076322A (ja) 2009-08-28 2017-11-24 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2020005901A Active JP6952810B2 (ja) 2009-08-28 2020-01-17 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2021157902A Active JP7167281B2 (ja) 2009-08-28 2021-09-28 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2022171242A Active JP7395693B2 (ja) 2009-08-28 2022-10-26 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2023201609A Active JP7605949B2 (ja) 2009-08-28 2023-11-29 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2024217551A Pending JP2025038063A (ja) 2009-08-28 2024-12-12 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2016041242A Active JP6251307B2 (ja) 2009-08-28 2016-03-03 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2017226255A Pending JP2018076322A (ja) 2009-08-28 2017-11-24 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2020005901A Active JP6952810B2 (ja) 2009-08-28 2020-01-17 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2021157902A Active JP7167281B2 (ja) 2009-08-28 2021-09-28 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2022171242A Active JP7395693B2 (ja) 2009-08-28 2022-10-26 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2023201609A Active JP7605949B2 (ja) 2009-08-28 2023-11-29 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2024217551A Pending JP2025038063A (ja) 2009-08-28 2024-12-12 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法

Country Status (30)

Country Link
US (9) US8349319B2 (enExample)
EP (4) EP2470199B1 (enExample)
JP (8) JP5955219B2 (enExample)
KR (6) KR102094253B1 (enExample)
CN (3) CN105999238A (enExample)
AU (6) AU2010286550B2 (enExample)
BR (1) BR112012004377A2 (enExample)
CA (1) CA2773133A1 (enExample)
CL (1) CL2012000495A1 (enExample)
CY (1) CY1122128T1 (enExample)
DK (3) DK3482767T3 (enExample)
ES (3) ES3052684T3 (enExample)
FI (2) FI3998078T3 (enExample)
FR (1) FR22C1062I2 (enExample)
HR (3) HRP20251310T1 (enExample)
HU (3) HUE057440T2 (enExample)
IL (4) IL314807A (enExample)
LT (4) LT3998078T (enExample)
LU (1) LUC00288I2 (enExample)
MX (2) MX356873B (enExample)
NL (1) NL301211I2 (enExample)
NO (1) NO2022054I1 (enExample)
PL (3) PL2470199T3 (enExample)
PT (3) PT3482767T (enExample)
RU (2) RU2731616C2 (enExample)
SI (3) SI2470199T1 (enExample)
SM (1) SMT202500432T1 (enExample)
TR (1) TR201911293T4 (enExample)
WO (1) WO2011025996A2 (enExample)
ZA (2) ZA201201435B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
PL2158322T3 (pl) 2007-06-06 2017-10-31 Genzyme Corp Terapia genowa dla lizosomalnych chorób spichrzeniowych
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
EP2571997A2 (en) 2010-05-21 2013-03-27 Ohmx Corporation Enzymatic activity of psa as diagnostic marker for prostate cancer
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
JP6243846B2 (ja) 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
ES2786128T3 (es) 2012-06-01 2020-10-08 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
MX370570B (es) 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
FR3070383B1 (fr) 2017-08-31 2021-08-20 Solable Appareil de traitement d'eau
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
CN117396517A (zh) * 2021-05-27 2024-01-12 梨树爱博思股份有限公司 与酸性鞘磷脂酶蛋白特异性结合的抗体

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
MXPA01006491A (es) 1998-12-23 2003-06-06 Thompson Boyce Plant Res Expresion de antigenos de superficie de hepatitis b inmunogenicos en plantas transgenicas.
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
BRPI0411291A (pt) * 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1897957A (zh) 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼－皮克病的基于陪伴分子的治疗
KR20070085291A (ko) 2004-10-13 2007-08-27 프로탈릭스 리미티드 식물 세포 배양에서 항체를 생산하는 시스템 및 방법
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CN101404927A (zh) * 2006-02-09 2009-04-08 建新公司 慢速脑室内递送
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
MX370570B (es) * 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Similar Documents

Publication Publication Date Title
Reid et al. A double‐blind, placebo‐controlled phase II study of the efficacy and safety of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease
IL266915B2 (en) Increasing dose replacement enzyme for the treatment of acid sphingomyelinase deficiency
Pandey et al. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study
Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
Flume et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health
Van Woensel et al. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis.
Chuchalin et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study
Sowers et al. The role of overweight and obesity in the cardiorenal syndrome
Glicklich et al. Heavy metal toxicity in chronic renal failure and cardiovascular disease: possible role for chelation therapy
Sun et al. Significant reduction of homocysteine level with multiple B vitamins in atrophic glossitis patients
Di Mario et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study
Holguin Arginine and nitric oxide pathways in obesity‐associated asthma
JP2014528474A5 (enExample)
US20240209097A1 (en) Treatment regimens
WO2021237299A9 (en) Methods of antipathogenic treatment
Giannopoulou et al. The NADPH oxidase NOX2 plays a role in periodontal pathologies
Marazziti et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients
Arita et al. Glyburide inhibits the bone resorption induced by traumatic occlusion in rats
Darwish et al. Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza
Berns Niacin and related compounds for treating hyperphosphatemia in dialysis patients
Arokianathan et al. Leptospirosis: a case report of a patient with pulmonary haemorrhage successfully managed with extra corporeal membrane oxygenation
Wang et al. Vibrio vulnificus infection complicated by acute-on-chronic liver failure: a case report
CA2436402A1 (en) Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
KR20220143662A (ko) 안지오텐신 조절 효소의 조절제로서의 진세노사이드 m1 및 코로나바이러스에 의해 유발된 증상을 포함하는 질환 또는 병태를 치료하기 위한 이의 용도
Bor et al. Long term biweekly 1 mg oral vitamin B12 ensures normal hematological parameters, but does not correct all other markers of vitamin B12 deficiency. A study in patients with inherited vitamin B12 deficiency